Boston Scientific granted approval to market Taxus Liberte stent

The company reported that the Health Canada’s Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use. The company plans to launch the product immediately in Canada.

David McFaul, Boston Scientific’s senior vice president, international, said: “Coupled with our proven paclitaxel-eluting technology, Taxus Liberte provides physicians with next-generation performance. We are delighted that Canadian physicians and patients can now benefit from this highly advanced technology for the treatment of coronary artery disease.”